Biotechnology company Biogen Idec surged on reports that it won market exclusivity for its top-selling multiple sclerosis drug in Europe. Major indexes have surged as solid corporate earnings, a strengthening economy and easy-money policies from the Federal Reserve have drawn investors to stocks.